Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies

Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, Marion Pepper, Daniel J. Campbell
doi: https://doi.org/10.1101/2023.01.03.23284167

Article Information

doi 
https://doi.org/10.1101/2023.01.03.23284167
History 
  • January 10, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Samuel D. Klebanoff1,2,
  2. Lauren B. Rodda2,
  3. Chihiro Morishima3,
  4. Mark H. Wener3,
  5. Yevgeniy Yuzefpolskiy1,
  6. Estelle Bettelli1,2,
  7. Jane H. Buckner1,2,
  8. Cate Speake1,
  9. Marion Pepper2 and
  10. Daniel J. Campbell1,2,*
  1. 1Benaroya Research Institute, Seattle, WA
  2. 2Department of Immunology, University of Washington School of Medicine, Seattle, WA
  3. 3Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA
  1. ↵*Corresponding Author: Daniel J. Campbell, Benaroya Research Institute, 1201 9th AVE, Seattle, WA 98101 USA dcampbell{at}benaroyaresearch.org
Back to top
Posted January 10, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, Marion Pepper, Daniel J. Campbell
medRxiv 2023.01.03.23284167; doi: https://doi.org/10.1101/2023.01.03.23284167
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area